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Introduction
Angiogenesis is the process of generating new capillary blood ves-
sels. In the adult, angiogenesis occurs under tight regulation in the
female reproductive system and during wound healing.
Uncontrolled neovascularization is observed in tumour growth and
in angioproliferative diseases [1]. Tumours cannot grow larger than
a few square millimetres as a mass unless a new blood supply is
induced [2]. Hence the control of the neovascularization process
may affect tumour growth and represents a novel approach to
angiogenesis-dependent disease therapy, including neoplasia [3].
Fibroblast growth factor-2 (FGF2) is a major heparin-binding
angiogenic growth factor that induces cell proliferation, chemo-
taxis and protease production in cultured endothelial cells [4]. 
In vivo, FGF2 shows angiogenic activity in different experimental
models [5] and modulates neovascularization during wound heal-
ing, inflammation, atherosclerosis and tumour growth [6], thus
representing a possible target for anti-angiogenic therapies [7, 8].
Accordingly, preclinical studies demonstrate that FGF2 antago-
nists inhibit tumour growth and vascularization [8–10].
FGF2 exerts its activity on endothelial cells by interacting with
high affinity tyrosine-kinase FGF receptors (FGFRs) [11] and low
affinity heparan sulphate proteoglycans (HSPGs) [12, 13], leading
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to the formation of productive HSPG/FGF2/FGFR ternary com-
plexes [14]. Therefore, natural and synthetic molecules able to
interfere with HSPG/FGF2/FGFR interaction may act as angiogene-
sis inhibitors (reviewed in [8]). To this respect, structural analysis
of FGFR ligands and screening of random phage epitope libraries
have led to the design of synthetic peptides able to target FGFRs
and compete for ligand binding, thus inhibiting the biological activ-
ity of FGF2 [15–22]. Similarly, FGF2-binding peptides have been
identified as in vitro and/or in vivo FGF2 antagonists [23–25].
The pattern recognition receptor pentraxin 3 (PTX3) is the pro-
totypic member of the long PTX family. It shares the C-terminal
PTX domain with short PTXs and possesses a unique N-terminal
domain. The biological activity of PTX3 is related to its ability to
interact with different ligands via its N-terminal or C-terminal
domain as a consequence of the modular structure of the protein
[26, 27]. Recent observations have shown that PTX3 binds FGF2
with high affinity and specificity [28]. Accordingly, PTX3 inhibits
FGF2-dependent endothelial cell proliferation in vitro and angiogen-
esis in vivo [28]. Also, PTX3 inhibits FGF2-dependent smooth mus-
cle cell activation and intimal thickening after arterial injury [29]. An
integrated approach that utilized PTX3-related synthetic peptides,
monoclonal antibodies and surface plasmon resonance analysis
has identified a FGF2-binding domain in the N-terminal extension
of PTX3 spanning the PTX3-(97–110) region, thus suggesting that
synthetic peptides related to the PTX3-(97–110) sequence may
represent novel PTX3-derived FGF2 antagonists [30].
Here, we have investigated the ability of various PTX3-
(97–110)-related synthetic peptides to interact with FGF2. The
results identify the short acetylated (Ac) pentapeptide Ac-
ARPCA-NH2 (in single letter code), corresponding to PTX3-
(100–104) sequence, as the minimal FGF2-binding peptide able
to interfere with FGF2/FGFR interaction. Accordingly, the peptide
is endowed with a significant FGF2-antagonist activity in vitro
and in vivo. Nuclear magnetic resonance (NMR) analysis of the
interaction mode of Ac-ARPCA-NH2 with FGF2 points to a pivotal
role of the N-terminal blocking methyl group and of the methyl
group of the side chain of Ala5 residue in FGF2 interaction. These
results will provide the basis for the design of novel PTX3-
derived FGF2 antagonists.
Methods
Chemicals
Human recombinant FGF2, human recombinant PTX3 and synthetic PTX3-
derived peptides (HPLC purity 95%) were provided by Tecnogen (Piana
di Monteverna, Caserta, Italy). FGF2 and PTX3 were expressed in
Escherichia coli and Chinese hamster ovary (CHO) cells, respectively, and
purified as described [31, 32]. Amino acid numbering starts from the
methionine residue in position 1 in the human PTX3 leader sequence.
Recombinant FGF8b was provided by M. Jalkanen (Biotie, Turku, Finland).
1,2-dioctanoyl-sn-glycerol (DAG), epidermal growth factor (EGF), 12-O-
tetradecanoyl phorbol 13-acetate (TPA) and vascular endothelial growth
factor-165 isoform (VEGF) were from Calbiochem (La Jolla, CA, USA).
FGF1 was from Peprotech (London, United Kingdom). Recombinant
human sFGFR1(IIIc)/Fc and sKDR/Fc chimeras were from RELIATech
GmbH (Braunschweig, Germany).
Cell cultures
Foetal bovine aortic GM7373 endothelial cells [28] were grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% foetal calf
serum (FCS). Wild-type CHO-K1 cells and the derived HSPG-deficient A745
CHO cell mutants [33], kindly provided by J.D. Esko (La Jolla, CA, USA),
were grown in Ham’s F-12 medium supplemented with 10% FCS. FGFR1-
transfected A745 CHO flg-1A cells, bearing about 30,000 FGFR1 mole-
cules/cell, were generated in our laboratory by transfection with the IIIc
variant of murine FGFR1 cDNA [34]. CHO cells stably overexpressing
murine FGFR1, FGFR2 or FGFR3, or human FGFR4 (10,000 to 100,000
receptors per cell) were generated in our laboratory by transfection with
the IIIc variant of the corresponding receptor cDNA [35]. Tumorigenic,
FGF2-overexpressing murine aortic endothelial FGF2-T-MAE cells [36]
were grown in DMEM plus 10% FCS.
Cell proliferation assays
GM7373 cell proliferation assay was performed as described [37]. Briefly,
subconfluent cultures of GM7373 cells were incubated in medium contain-
ing 0.4% FCS plus FGF2 (0.55 nM) in the absence or the presence of dif-
ferent antagonists. In a second set of experiments, GM7373 cells were
incubated in medium containing 0.4% FCS plus the indicated mitogenic
stimuli in the absence or the presence of Ac-ARPCA-NH2 peptide (66 M).
Furthermore, FGFR1-, FGFR2-, FGFR3- and FGFR4-transfected CHO cells
were seeded in 96-well plates at 30,000 cells/cm2. After 16 hrs, cells were
incubated in medium containing 0.4% FCS plus FGF2 (0.55 nM) in the
absence or the presence of Ac-ARPCA-NH2 or Ac-ARPSA-NH2 peptides
(both at 300 M). For all the assays, cells were trypsinized and counted in
a Burker chamber after 24 hrs of incubation.
FGF2-mediated cell–cell adhesion assay
This assay was performed as described previously [38], with minor modi-
fications. Briefly, wild-type CHO-K1 cells were seeded in 24-well plates at
150,000 cells/cm2. After 24 hrs, cell monolayers were washed with PBS
and incubated with 3% glutaraldehyde in PBS for 2 hrs at 4C. Fixation was
stopped with 0.1 M glycine, and cells were washed extensively with PBS.
Then, A745 CHO flg-1A cells (50,000 cells/cm2) were added to CHO-K1
monolayers in serum-free medium plus 10 mM EDTA with or without 
1.66 nM FGF2 in the absence or presence of increasing concentrations of
the competitor under test. After 2 hrs of incubation at 37C, unattached
cells were removed by washing twice with PBS, and A745 CHO flg-1A cells
bound to the CHO-K1 monolayer were counted under an inverted micro-
scope at 125 magnification. Adherent A745 CHO flg-1A cells have a
rounded morphology and can be easily distinguished from the confluent
CHO-K1 monolayer lying underneath on a different plane of focus. Data are
expressed as the mean of the cell counts of three microscopic fields cho-
sen at random. All experiments were performed in triplicate and repeated
twice with similar results.
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Western blot analysis
Mitogen-activated protein kinase (ERK1/2) phosphorylation assay was per-
formed as described [34] with minor modifications. Briefly, GM7373 cells
were grown to 80–90% confluence in 48-well plates and starved for 2 hrs
in medium containing 0.4% FCS. After pre-incubation for 30 min. at 37C
with or without synthetic peptides (1.0 mM final concentration), cells were
treated with FGF2 (0.17 nM) for 10 min. without changing the medium. At
the end of the incubation, cells were washed briefly with ice-cold PBS,
lysed in reducing SDS-PAGE sample buffer, sonicated at 50 W for 20 sec.,
and boiled. Samples were analysed by Western blotting using a mono-
clonal anti-phospho-ERK1/2 antibody and a monoclonal anti-ERK2 antibody
(both at 1/1000 dilution, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), followed by incubation with peroxidase-conjugated goat antimouse
IgG antibody (1/5000 dilution, Sigma, St. Louis, MO, USA).
BIAcore binding assay
A BIAcore X apparatus (BIAcore Inc., Piscataway, NJ, USA) was used to set
up four different experimental models. (i) PTX3-derived peptides were
analysed for their capacity to inhibit the binding of free FGF2 to PTX3
immobilized to the sensor chip. To this purpose, PTX3 (2.2 M in 10 mM
sodium acetate, pH 2.4) was allowed to react with a flow cell of a CM4 sen-
sor chip that was previously activated with a mixture of 0.2 M N-ethyl-N-
(3-dimethylaminopropyl)-carbodiimide hydrochloride and 0.05 M N-
hydroxysuccinimide (35 l, flow rate 10 l/min.). These experimental con-
ditions allowed the immobilization of ~0.1 pmol/mm2 of PTX3. Similar
results were obtained for immobilization of gelatin, here used as a negative
control and for blank subtraction. After ligand immobilization, matrix neu-
tralization was performed with 1.0 M ethanolamine (pH 8.5) (35 l, flow
rate 10 l/min.). (ii) PTX3-derived peptides were analysed for their capac-
ity to inhibit the binding of free FGF2 to immobilized heparin, prepared as
described previously [39]. Briefly, size-defined heparin (13.6 kD) was
biotinylated on its reducing end, and a flow cell of a CM3 sensor chip was
activated with streptavidin. Then, biotinylated heparin was allowed to react
with the streptavidin-coated sensor chip. (iii) PTX3-derived peptides were
analysed for their capacity to inhibit the binding of free FGF2 to immobi-
lized FGFR1. To this purpose, protein A (100 g/ml in 10 mM sodium
acetate, pH 4.8) was allowed to react with a flow cell of a CM5 sensor chip
that was previously activated with a mixture of 0.2 M N-ethyl-N-(3-
dimethylaminopropyl)-carbodiimide hydrochloride and 0.05 M N-hydroxy-
succinimide (35 l, flow rate 10 l/min.). Following neutralization with 1.0
M ethanolamine (pH 8.5) (35 l, flow rate 10 l/min.), recombinant human
sFGFR1(IIIc)/Fc chimera (100 g/ml) was allowed to react with the protein
A-coated sensor chip. Then, a 30-sec. injection of a mixture (7 l, flow rate
15 l/min.) of 0.2 M N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide
hydrochloride and 0.05 M N-hydroxysuccinimide was performed, followed
immediately by a 30-sec. injection of 1.0 M ethanolamine (pH 8.5) (7 l,
flow rate 15 l/min.). These experimental conditions allowed the immobi-
lization of ~0.003 pmol/mm2 of sFGFR1(IIIc)/Fc chimera. Protein A-coated
sensorchip was used as a negative control and for blank subtraction. (iv)
PTX3-derived peptides were analysed for their capacity to inhibit the bind-
ing of free VEGF to immobilized VEGFR2/KDR. To this purpose, sKDR/Fc
chimera (20 g/ml in 10 mM sodium acetate, pH 5.3) was allowed to react
with a flow cell of a CM5 sensor chip that was previously activated with a
mixture of 0.2 M N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide
hydrochloride and 0.05 M N-hydroxysuccinimide (35 l, flow rate 10
l/min.). These experimental conditions allowed the immobilization of
~0.06 pmol/mm2 of sKDR/Fc chimera. After ligand immobilization, matrix
neutralization was performed with 1.0 M ethanolamine (pH 8.5) (35 l, flow
rate 10 l/min.). Depending upon the experimental model, different doses
of FGF2 were injected in the presence of increasing concentrations of the
peptide under test in 0.01 M Hepes pH 7.4 plus 0.005% surfactant P20,
0.15 M NaCl, 3 mM ethylenediaminetetraacetic acid (HBS-EP buffer).
Injection lasted for 4 min. to allow the association of FGF2 with the immo-
bilized ligand. In parallel experiments, 45 nM VEGF was injected for 4 min.
on the sKDR/Fc surface in the absence or presence of 300 M Ac-ARPCA-
NH2 peptide. The response (in RU) was recorded at the end of injection, and
binding data were plotted as percentage of maximal bound analyte.
Chick embryo chorioallantoic membrane assay
Alginate beads (5 l) containing vehicle or 8 pmoles of FGF2 with or with-
out synthetic peptides (117 nmoles) were prepared as described [40] and
placed on top of the chicken embryo chorioallantoic membrane (CAM) of
fertilized White Leghorn chicken eggs at day 11 of incubation (10 eggs per
experimental group). After 72 hrs, blood vessels converging towards the
implant were counted by two observers in a double-blind fashion under a
stereomicroscope (STEMI-SR, 2/0.12; Zeiss, Arese, Italy).
Zebrafish/tumour xenograft angiogenesis assay
This was performed as described previously [41, 42]. Briefly, a zebrafish
(Danio rerio) breeding colony (wild-type AB strain) was maintained at 28C
at the Zebrafish Facility of the University of Brescia. Dechorionated
embryos at 48 hrs after fertilization were anaesthetized with 0.04 mg/ml of
tricaine (Sigma) and injected with 1000 to 2000 FGF2-T-MAE cells per
embryo resuspended in 3–4 nl of Matrigel (Becton Dickinson, Milan, Italy)
in the absence or in the presence of Ac-ARPCA-NH2 or Ac-ARPSA-NH2
peptides (each at 75 M) using a Picospritzer microinjector (Eppendorf,
Hamburg, Germany). After 24 hrs, zebrafish embryos were fixed in 4%
paraformaldehyde for 2 hrs at room temperature and stained for endoge-
nous alkaline phosphatase activity [43]. Then, embryos were mounted in
agarose-coated Petri dishes, photographed under an epifluorescence Leica
MZ16 F stereomicroscope equipped with a DFC480 digital camera (Leica,
Solms, Germany), and scored for a positive angiogenic response defined
as the presence of a new alkaline phosphatise-positive microvasculature
projecting from the sub-intestinal vessel plexus of the embryo and infiltrat-
ing the tumour graft [41, 42].
Nuclear magnetic resonance spectroscopy
Ac-ARPCA-NH2, Ac-GRPCA-NH2, Ac-ARPCG-NH2, Ac-ARPSA-NH2 and the
non-acetylated H-ARPCA-NH2 peptides were dissolved at 1.6 mM final
peptide concentration in 30 mM phosphate buffer, 40 mM NaCl, pH 6.8.
1,4-Dithiothreitol (DTT) was added to peptide solutions at a final concen-
tration of 8 mM in order to avoid the production of dimers through the 
formation of disulphide bridges between the free cysteines. In order to
investigate the interaction between peptides and FGF2, samples of 50 M
protein were prepared in the presence of 1.9 mM peptide in 30 mM phos-
phate buffer (95% D2O, 5% H2O), 8.0 mM DTT, 40 mM NaCl, pH 6.8.
All NMR spectra were recorded on DMX spectrometer (Bruker, Ettlingen,
Germany) operating at 500 MHz equipped with a triple resonance
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probehead, incorporating gradients in the z-axis. All data were collected
at 280 K on a spectral width of 6510 Hz. TOCSY, ROESY and NOESY
spectra were recorded using standard sequences [44, 45]. A spin lock
time of 80 msec. was used for TOCSY, mixing times of 150 and 
250 msec. were used for ROESY spectra, while different NOESY spectra
were collected with mixing times of 100, 180, 250 and 400 msec. on
peptide alone and in the presence of FGF2 at 1:40 ratio at 280 and 
290 K. Longitudinal relaxation times T1 of the peptides were measured
when the FGF2 protein was present. The standard inversion recovery
method was used for the measurements with a relaxation delay of 8 sec.
Data points (16 K) were acquired to cover a sweep width of 10 ppm.
Data were analysed using Bruker Topspin software. T1 values were
found to be rather constant along the peptide side chains in a range of
0.4–0.6 sec., except for longer T1 observed for methyl protons of 
N-terminal acetyl group (1.1 sec.).
For the acquisition of saturation transfer difference (STD) NMR 
[45, 46], a 1D pulse sequence incorporating a T1 filter to remove disturb-
ing protein signals was used. Spectra were recorded with a spectral width
of 6510 Hz and 32 K data points. On-resonance irradiations were per-
formed at different frequencies in the aromatic (3325 Hz) and methyl
(	216 Hz, 	150 Hz) regions and off-resonance irradiation was per-
formed at –20,000 Hz, using a series of Gaussian pulses with a 1% trun-
cation and 50 msec. duration to give total saturation times of 0.25, 0.5, 1,
2, 2.5, 3, 4, 4.5 sec. Given the low molecular weight of FGF2 (18 kD), a
compromise was found between the high power saturation pulses needed
for full protein saturation by spin-diffusion and the low power saturation
pulses needed to avoid direct irradiation of peptide resonances. The selec-
tive saturation of the protein was checked by collecting a STD control
spectrum in the same experimental conditions on the ligand alone which
did not show any signal, thus excluding direct excitation of the peptide
resonances. The duration of the T1 filter was 30 msec. STD NMR spec-
tra were acquired with a total of 192 transients in addition to 32 scans to
allow the sample to come to equilibrium. STD spectrum was obtained by
subtraction of saturated spectrum from the reference spectrum obtained
with off resonance irradiation. STD intensities of individual signals (ISTD)
were measured relative to the corresponding signal intensity in the refer-
ence spectrum (I0) and described by STD factor ASTD 
 (ISTD)/I0. Titration
of FGF2 protein with Ac-ARPCA-NH2 was performed by adding different
amounts of a stock solution of the peptide to a 50 M FGF2 sample. STD
experiments were acquired on samples ranging between 1:10 and 1:100
FGF2:Ac-ARPCA-NH2 molar ratios at 280 K on a 500 MHz spectrometer
using 3 sec. saturation time.
Computational methods
A conformational analysis was performed on Ac-ARPCA-NH2 peptide
based on low mode Montecarlo procedure with OPLS-AA force field
using water as implicit solvent (software: Macromodel v.9.5 Schrodinger
llc). 3000 conformers within 10 kcal/mol were analysed and divided into
three clusters. The most stable conformational family (E within 
3 kcal/mol) showed a type-I -turn between Pro and Cys residues and
the nearest distance between Ala1 and Ala5 (mean value 
 6.6  1.5 Å´),
whereas the other two families showed a progressive tendency to form a
random coil conformation. The global minimum conformation of Ac-
ARPCA-NH2 was permitted to rotate at N- and C-terminal portion and
superimposed to the crystal structure of FGFR1 (PDB code: 1FQ9) in the
-sheet portion 164–170 of the hydrophobic domain D2 of the receptor.
The complex was then minimized and the peptide maintained its charac-
teristic -turn after minimization.
Results
Identification of PTX3-(100–104) as a minimal
linear FGF2 binding sequence
Previous observations had shown that a 14 mer PTX3-(97–110)
peptide binds to FGF2, thus preventing FGF2/PTX3 interaction and
inhibiting FGF2-dependent endothelial cell proliferation in vitro and
angiogenesis in vivo [30]. On this basis, in an attempt to identify
novel FGF2-antagonist(s), four acetylated (Ac) overlapping 
synthetic peptides based on the amino acid sequences 
PTX3-(97–107), PTX3-(100–113), PTX3-(100–104) and PTX3-
(104–113) were compared with PTX3-(97–110) peptide for their
capacity to interact with FGF2 (Table 1). In a first set of experi-
ments, surface plasmon resonance was exploited to assess the
ability of increasing concentrations of these peptides (ranging from
3 to 3000 M) to compete for the binding of free FGF2 to PTX3
immobilized onto a BIAcore sensor chip [30] (Table 1). Among the
peptides tested, PTX3-(100–104) was the most active in prevent-
ing FGF2/PTX3 interaction (ID50 
 120 M), PTX3-(97–107) and
PTX3-(100–113) showed an activity similar to the parental peptide
PTX3-(97–110) (ID50 
 300–500 M), whereas PTX3-(104–113)
was almost inactive (ID50 
 2.0 mM). In keeping with their ability
to bind FGF2 in the mobile phase, PTX3-(97–110), PTX3-
(100–113), PTX3-(97–107) and PTX3-(100–104) all inhibited the
mitogenic activity exerted by FGF2 on endothelial GM7373 cells in
a dose-dependent manner (ID50 values ranging between 15 and 
50 M), whereas PTX3-(104–113) was ineffective (Table 1). Taken
together, the data suggest that the amino acid sequence ARPCA (in
single letter code), which is present in all the active peptides and
absent in the inactive PTX3-(104–113) peptide (Table 1), may rep-
resent a minimal linear FGF2-binding amino acid sequence in the
PTX3-(97–110) region endowed with FGF2 antagonist activity.
To assess the relevance of each amino acid residue of 
Ac-ARPCA-NH2 pentapeptide for FGF2 interaction, a series of syn-
thetic peptides carrying different amino acid substitutions were
tested for their FGF2 antagonist activity as evaluated by the capacity
to prevent FGF2/PTX3 interaction by surface plasmon resonance
analysis and to inhibit FGF2-dependent endothelial cell prolifera-
tion. As shown in Table 2, the partially scrambled Ac-APCRA-NH2
and the scrambled Ac-PARAC-NH2 peptides showed an inhibitory
activity that was significantly reduced or abolished in both assays,
pointing to the relevance of the relative position of each residue for
the FGF2 antagonist capacity of the peptide. Also, the FGF2 antag-
onist activity was dramatically reduced for the non-acetylated 
H-ARPCA-NH2 peptide and for the Ac-ARPCG-NH2 and Ac-
GRPCG-NH2 peptides, but not for the Ac-GRPCA-NH2 peptide,
indicating a role for the N-terminal blocking methyl group and for
the methyl group of the side chain of Ala5 residue in FGF2 inter-
action. The activity was lost also when the Arg2 residue was
replaced in Ac-ALPCA-NH2 peptide, when the Pro3 residue was
replaced in Ac-ARACA-NH2 and Ac-ARGCA-NH2 peptides, or when
the Cys4 residue was replaced in Ac-ARPSA-NH2, Ac-ARPVA-NH2
and Ac-ARPMA-NH2 peptides, thus underlying the role of the RPC
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amino acid sequence in Ac-ARPCA-NH2/FGF2 interaction.
Interestingly, the FGF2 antagonist activity was lost also when the
ARPCA region was mutated within synthetic peptides based on the
amino acid sequence PTX3-(97–110), as observed for peptides
Ac-ESLGRPCGPGAPAE-NH2, Ac-ESLARGCAPGAPAE-NH2 and Ac-
ESLARPSAPGAPAE-NH2 when compared to the wild-type Ac-
ESLARPCAPGAPAE-NH2 peptide (data not shown). Similar results
were obtained when the same amino acid substitutions were per-
formed in the longer FGF2-antagonist PTX3-(82–110) peptide
[30], thus confirming the importance of the linear ARPCA
sequence in FGF2 interaction (data not shown).
Taken together, the results identify the Ac-ARPCA-NH2 pen-
tapeptide as a synthetic FGF2 antagonist. N-terminal blocking and
Ala5 side-chain methyl groups, as well as RPC residues, all appear
to play a non-redundant role in FGF2 interaction. On this basis, the
Ac-ARPCA-NH2 pentapeptide (hereafter referred to as ARPCA)
was characterized further for its capacity to interact with FGF2 and
to antagonize its biological activity.
ARPCA peptide inhibits FGF2/FGFR1 interaction
PTX3 is able to inhibit the mitogenic activity exerted by FGF2 and
by other members of the FGF family on endothelial cells, without
affecting the activity of unrelated mitogens [28]. On this basis,
ARPCA was assessed for its capacity to affect the proliferation of
endothelial GM7373 cells exposed to different mitogenic stimuli.
In these and following biological experiments, the inactive Ac-
ARPSA-NH2 (hereafter referred to as ARPSA) was used as a neg-
ative control peptide. As shown in Fig. 1(A), ARPCA inhibits
GM7373 cell proliferation triggered by FGF2, FGF8b and with a
less efficiency by FGF1, whereas it does not affect the mitogenic
activity of VEGF, EGF, DAG, TPA and serum. No inhibition was
instead exerted by control peptide ARPSA on any mitogen.
Moreover, in keeping with the capacity of FGF2 to interact with all
four members of the FGFR family [47], ARPCA, but not ARPSA,
inhibits the proliferation triggered by FGF2 in CHO cells stably
transfected with the FGFR1, FGFR2, FGFR3 or FGFR4 isoforms
[35] (Fig. 1B). These data demonstrate that, as for PTX3, the
inhibitory activity of ARPCA is limited to the FGF/FGFR system and
it is not due to a generic antiproliferative/toxic effect.
FGFs exert their biological activity by leading to the formation
of a productive HSPG/FGF/FGFR ternary complex [14]. On this
basis, to investigate the molecular mechanism responsible of its
FGF2 antagonist activity, ARPCA was evaluated for the capacity to
prevent the formation of HSPG/FGF2/FGFR1 ternary complexes in
a cell–cell adhesion model in which FGF2 mediates the interaction
of HSPG-deficient CHO cells stably transfected with FGFR1 to a
monolayer of CHO-K1 cells expressing HSPGs but not FGFRs [38].
As shown in Fig. 2(A), ARPCA, but not ARPSA, exerts a significant
inhibitory activity on FGF2-mediated cell–cell adhesion (ID50 equal
to 50 M and 1.0 mM for the two peptides, respectively), thus
indicating the capacity of the peptide to interfere with
HSPG/FGF2/FGFR1 complex formation. Accordingly, ARPCA, but
not ARPSA, inhibits FGF2-induced ERK1/2 phosphorylation in
GM7373 cells [34], thus demonstrating the capacity of the peptide
to affect FGFR signalling (Fig. 2B).
To assess whether the inhibition of HSPG/FGF2/FGFR1 complex
formation by ARPCA is due to its ability to hamper HSPG/FGF2
and/or FGF2/FGFR1 interactions, the peptide was investigated for
the capacity to prevent the binding of free FGF2 to heparin or to a
sFGFR1(IIIc)/Fc chimera both immobilized to BIAcore sensor chips.
As shown in Fig. 2(C), ARPCA does not affect FGF2/heparin interac-
tion (ID50  1.0 mM) whereas it significantly inhibits the binding of
FGF2 to the immobilized receptor with a potency (ID50 
 30 M)
similar to that found when the peptide was tested for its capacity to
inhibit FGF2-mediated endothelial cell proliferation (ID50 
 15 M,
see Table 1). No effect was instead exerted by ARPSA on both sen-
sor chips. In a control experiment, ARPCA did not prevent the bind-
ing of VEGF to an immobilized sKDR/Fc chimera (data not shown),
in keeping with the incapacity of the peptide to affect the mitogenic
activity exerted by VEGF on endothelial cells (see Fig. 1A).
Taken together these data indicate that the FGF2 antagonist
activity of ARPCA is related to its ability to interfere with
Table 1 FGF2-antagonist activity of PTX3-derived synthetic peptides
PTX3 peptide Amino acid sequence*
FGF2/PTX3 interaction 
in BIAcore ID50 (M)
FGF2-dependent EC 
proliferation ID50 (M)
PTX3-(97–110) Ac-ESLARPCAPGAPAE-NH2 300 20
PTX3-(97–107) Ac-ESLARPCAPGA-NH2 300 50
PTX3-(100–113) Ac-ARPCAPGAPAEARL-NH2 500 10
PTX3-(100–104) Ac-ARPCA-NH2 120 15
PTX3-(104–113) Ac-APGAPAEARL-NH2 2000 1000
Peptides were tested for their capacity to inhibit the interaction of free FGF2 (150 nM) with PTX3 immobilized onto a BIAcore sensorchip and to inhibit
the mitogenic activity exerted by FGF2 on endothelial GM7373 cells. The experiments were performed with concentrations of peptide ranging between
3 and 3000 M and between 3 and 1000 M for the two assays, respectively, and ID50 values were calculated from the plotted dose–response
curves. Data are representatives of two to three independent experiments in triplicate.
*Amino acid sequences are shown in the single letter code and numbering starts from the methionine residue in position 1 in the PTX3 leader sequence.
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FGF2/FGFR1 interaction without affecting the ability of the growth
factor to interact with heparin/HSPGs. This results in the impair-
ment of the formation of a productive HSPG/FGF/FGFR ternary
complex, with consequent inhibition of FGFR signalling and FGF2-
mediated biological activity.
ARPCA peptide inhibits the angiogenic activity 
of FGF2 in vivo
In a first set of experiments, the capacity of ARPCA to affect FGF2-
induced neovascularization in vivo was investigated in a chick
embryo CAM assay [48]. In this assay, alginate beads adsorbed
with FGF2 (8.0 pmoles/embryo) exert a potent angiogenic
response when compared with beads adsorbed with vehicle
(macroscopic vessels converging towards the implant being equal
to 36  4 and 6  3 vessels/embryo, respectively). In keeping
with the in vitro observations, the angiogenic response elicited 
by FGF2 was significantly reduced by the addition of 117 nmoles
of ARPCA peptide in the FGF2 implants (17  7 vessels/embryo,
P 
 0.007). No effect was instead exerted by control ARPSA 
(33  5 vessels/embryo) (Fig. 3A).
In a second set of experiments, ARPCA and ARPSA were 
characterized for their ability to affect the angiogenic response
triggered by tumorigenic FGF2-overexpressing mouse aortic
endothelial (FGF2-T-MAE) cells in a novel zebrafish embryo/tumour
graft model [41, 42]. To this purpose, FGF2-T-MAE cells were
resuspended in Matrigel in the absence or in the presence of the
peptide under test (300 fmoles/embryo). Then, cells were micro -
injected in zebrafish embryos at 48 hrs after fertilization
Table 2 FGF2-antagonist activity of Ac-ARPCA-NH2 peptide mutants
Peptides were tested for their capacity to inhibit the interaction of free FGF2 (150 nM) with PTX3 immobilized onto a BIAcore sensor chip and 
to inhibit the mitogenic activity exerted by FGF2 (0.55 nM) on endothelial GM7373 cells. The experiments were performed with concentrations of
peptide ranging between 3 and 3000 M and between 3 and 1000 M for the two assays, respectively, and ID50 values were calculated from the
plotted dose–response curves. Data are representatives of two to three independent experiments in triplicate.
Assay
Amino acid substitution(s)
Synthetic peptide 
(amino acid sequence)
FGF2/PTX3 interaction 
in BIAcore ID50 (M)
FGF2-dependent EC 
proliferation ID50 (M)
None
Ac-ARPCA-NH2 120 15
Amino acid position
Ac-APCRA-NH2 800 100
Ac-PARAC-NH2 1000 1000
N-terminus blockade
H-ARPCA-NH2 2000 500
Ala residues
Ac-GRPCA-NH2 80 15
Ac-ARPCG -NH2 1000 1000
Ac-GRPCG-NH2 3000 1000
Arg residue
Ac-ALPCA-NH2 3000 1000
Pro residue
Ac-ARACA-NH2 3000 1000
Ac-ARGCA-NH2 1500 500
Cys residue
Ac-ARPSA-NH2 3000 1000
Ac-ARPVA-NH2 3000 1000
Ac-ARPMA-NH2 3000 1000
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(1000–2000 cells/embryo) through the perivitelline space between
the yolk and the periderm (duct of Cuvier area), close to the devel-
oping subintestinal vessels (SIV). As shown in Fig. 3(B), FGF2-T-
MAE cell xenografts induced a potent angiogenic response, char-
acterized by newly-formed alkaline phosphatase-positive blood
vessels projecting from the SIV plexus, in 87% of injected
zebrafish embryos (n 
 19). This response was significantly
reduced to 19% of injected embryos by ARPCA (n 
 16; P 

0.002) but not by ARPSA (72% of positive responses; n 
 14).
ARPCA/FGF2 interaction mode by NMR spectroscopy
In an attempt to characterize the structural basis and the nature of
binding interactions, different NMR experiments were performed
on ARPCA peptide alone and in the presence of FGF2. A first set of
standard two-dimensional experiments (TOCSY, ROESY, NOESY)
were used to assign proton chemical shifts of ARPCA peptide in
aqueous solution (Table 3). The analysis of the ROESY experi-
ment, showing only intra-residue and sequential cross-peaks,
indicates that ARPCA peptide does not occur in a single, well-
defined conformation in aqueous solution. The peptide bond pre-
ceding the proline residue is in the trans configuration, as deduced
from the presence of the H Arg2–H1/ H2 Pro3 cross-peaks.
The absence of a stable secondary structure for the peptide is con-
firmed by the measure of JHN-H coupling constants, showing
average values in the range 5–7 Hz.
In order to map the peptide residues making direct contacts
with FGF2, STD NMR methods were applied [46]. STD NMR
experiments were performed in the presence of DDT in order to
avoid the formation of disulphide bridges between free cysteines.
The STD spectrum of ARPCA peptide in the presence of FGF2
proves that methyl protons of Ala1, Ala5 and of the N-terminal
Fig. 1 Effect of Ac-ARPCA-NH2 on the biological activity of the
FGF2/FGFR system. (A) GM 7373 cells were treated with FGF2 (0.55 nM),
FGF1 (1.66 nM), FGF8b (1.66 nM), VEGF (0.7 nM), EGF (0.6 nM), DAG
(15 M), TPA (8.0 nM) or 10% FCS in the absence or in the presence of
Ac-ARPCA-NH2 (66 M). (B) CHO cells overexpressing FGFR1, FGFR2,
FGFR3 or FGFR4 were treated with FGF2 (0.55 nM) in the absence or in
the presence of Ac-ARPCA-NH2 (black bars) or Ac-ARPSA-NH2 (open
bars) (both peptides at 300 M). In both assays, cells were trypsinized
and counted 24 hrs after the stimulus. Data (mean  S.D. of triplicate
observations) are expressed as percentage of cell proliferation measured
in the absence of the peptide under test.
Fig. 2 Effect of Ac-ARPCA-NH2 on the HSPG/FGF2/FGFR1 complex and
FGFR signaling. (A) HSPG-deficient, FGFR1-transfected CHO cells were
added to wild-type CHO-K1 monolayers in serum-free medium with FGF2
(1.66 nM) in the presence of Ac-ARPCA-NH2 () or Ac-ARPSA-NH2 ()
peptides. After 2 hrs of incubation at 37C, the cells bound to the mono-
layer were counted under an inverted microscope. Experiments were per-
formed in triplicate and were repeated twice with similar results. (B)
GM7373 cells were treated with vehicle (a), 0.17 nM FGF2 (b), or FGF2
plus Ac-ARPCA-NH2 (c) or Ac-ARPSA-NH2 (d) peptides (both at 1.0
mM). After 10 min., cell extracts were analysed by Western blotting using
anti-phospho-ERK1/2 and anti-ERK2 antibodies. (C) Sensogram overlay
showing the binding of FGF2 (150 nM or 50 nM, respectively) to heparin-
coated (upper panel) or sFGFR1(IIIc)/Fc chimera-coated (lower panel)
BIAcore sensor chips in the absence (_____) or in the presence of Ac-
ARPCA-NH2 (- - -) or Ac-ARPSA-NH2 (……) peptides (both at 1.0 mM).
The response (in RU) was recorded as a function of time.
2116 © 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
blocking acetyl group receive saturation transfer, giving rise to
STD NMR signals (Fig. 4A). The hydrophobic patch defined by the
three methyl groups is therefore involved in binding to the protein
surface. In an attempt to compare the relative contribution of each
methyl group to the contact area, a build-up curve of the satura-
tion degree (STD factor, ASTD) against the saturation time was per-
formed for each NMR signal (Fig. 4B). It has been previously
reported that both the build–up rate and the height of STD factor
plateau are strongly affected by T1 relaxation of the single protons
[49]. Indeed at long saturation times higher STD factors are meas-
ured for protons with higher T1 values while at short saturation
times, if all sites of the protein are sufficiently saturated, ASDT
reflects the average proximity of the ligand protons to the protein
surface. Due to the relatively low molecular weight of FGF2, satu-
ration times lower than 1 sec. were not sufficient to saturate the
entire protein and to monitor any STD effect. However, from the
behaviour of the ASTD curves obtained for Ala1 and Ala5 methyl
signals, showing comparable T1 values, a similar contribution to
contact area of Ala1 and Ala5 methyls can be inferred. The prox-
imity of the two methyls to FGF2 protein was also evaluated by
performing a series of STD titration experiments and calculating
the STD factors as a function of ARPCA excess. STD factors
obtained for the different chemical groups (Fig. 4C) suggest that
the proximity to the protein of the methyl groups of the two Ala
residues is comparable. A higher STD amplification factor is
observed for the N-terminus acetyl group but the result could be
biased by the longer relaxation time T1 of this group.
Fig. 3 Anti-angiogenic activity of Ac-ARPCA-NH2. (A) CAMs (10 eggs per
group) were implanted at day 11 with alginate beads containing 8 pmoles
FGF2 in the absence (a) or in the presence of 117 nmoles of Ac-ARPCA-
NH2 (b) or Ac-ARPSA-NH2 (c). After 72 hrs, CAMs were photographed in
ovo (original magnification, 5) and the blood vessels converging
towards the implant were counted (black bars). Alginate beads contain-
ing vehicle alone were used as controls (open bar). (B) Zebrafish
embryos (14–19 embryos per group) were injected with pro-angiogenic
tumour FGF2-T-MAE cells resuspended in a Matrigel solution in the
absence (a) or in the presence of 300 fmoles/embryo of Ac-ARPCA-NH2
(b) or Ac-ARPSA-NH2 (c). After 24 hrs, the percentage of embryos showing
a positive angiogenic response, characterized by the growth of alkaline
phosphatase-positive SIVs converging versus the graft (*), was evalu-
ated (black bars). Embryos injected with Matrigel alone were used as
negative controls (open bar). *, P  0.05 or better, Student’s t-test.
Table 3 1H NMR chemical shifts (ppm) of Ac-ARPCA-NH2 peptide
NMR spectra were recorded at 280 K in 30 mM sodium phosphate
buffer, pH 6.8 on a 500 MHz Bruker spectrometer.
Amino acid
residue
HN H H H Others
N-terminus Ac 2.00
Ala1 8.41 4.23 1.33
Arg2 8.55 4.61 1.83 1.71 H 3.20; Hε 7.33
Pro3 4.43 2.29–1.91 2.02 H 3.81–3.64
Cys4 8.66 4.44 2.93
Ala5 8.63 4.26 1.40
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In order to investigate the role of the different methyl groups in
FGF2 interaction, STD NMR experiments were performed with the
ARPCA peptide mutants Ac-GRPCA-NH2, Ac-ARPCG-NH2 and
non-acetylated H-ARPCA where the single methyl groups were
individually removed. The STD spectrum of Ac-GRPCA-NH2 indi-
cates that the peptide is still able to bind FGF2, even though with
an affinity slightly lower than ARPCA. The binding mechanism is
conserved and the peptide contact area involves the methyl pro-
tons of Ala5 and of the N-terminal blocking acetyl group (Fig. 4A
and Table 4). On the contrary, the substitution of Ala5 with a Gly
residue or the removal of N-terminal acetyl group induce a more
dramatic decrease of interaction as deduced from the absence of
STD signals for Ac-ARPCG-NH2 and H-ARPCA-NH2, respectively
(Fig. 4A). In conclusion, the NMR results point to a hydrophobic
interaction of ARPCA with FGF2 mediated by three methyl groups,
whose relative position appears to be crucial for FGF2 recognition.
However, the three methyls play different roles in the interaction
with the protein. Indeed, while the methyls of Ala5 and of the 
N-terminal blocking acetyl group are essential for FGF2 interac-
tion, the methyl of Ala1 appears to be dispensable, as shown by
the retained FGF2-binding ability of the Ac-GRPCA-NH2 mutant.
Discussion
PTX3 comprises a PTX-like C-terminal 203-amino acid domain
and an N-terminal 178 amino acid extension with no significant
homology with any other protein [26]. Previous observations had
shown that PTX3 binds FGF2 with high affinity and selectivity, thus
hampering the interaction of the growth factor with its cell surface
receptors and inhibiting its activity on target cells [28]. Indeed,
PTX3 suppresses the angiogenic activity exerted by FGF2 on
endothelial cells [27] and prevents FGF2-dependent smooth mus-
cle cell activation [29], thus representing an endogenous FGF2
inhibitor in different pathophysiological settings and a candidate
for the design of novel specific FGF2 antagonists [27].
FGF2 interaction is mediated by the linear amino acid sequence
PTX3-(97–110) present in the N-terminal extension on PTX3 [30].
Accordingly, the synthetic peptide PTX3-(97–110) and the longer
PTX3-(82–110) peptide prevent FGF2/PTX3 interaction by binding
FGF2, thus inhibiting FGF2-dependent endothelial cell proliferation
in vitro and angiogenesis in vivo [30].
Here we have investigated the ability of shorter PTX3-
(97–110)-related synthetic peptides to interact with FGF2. The
results identify the acetylated pentapeptide ARPCA, corresponding
to the amino acid sequence 100–104 in the PTX3 molecule, as the
minimal FGF2-binding peptide able to interfere with the biological
activity of the growth factor. The peptide prevents the interaction
of FGF2 with the full length PTX3 protein and inhibits the mito-
genic activity of the growth factor in endothelial cells. This appears
to be the consequence of the ability of the peptide to hamper the
formation of a productive HSPG/FGF2/FGFR1 ternary complex by
inhibiting the binding of FGF2 to its high affinity tyrosine kinase
FGFR1 without affecting the interaction with cell surface low affin-
ity HSPGs. This is in keeping with previous observations about the
mechanism responsible for the FGF2 antagonist activity of the full
length PTX3 protein [28]. The in vitro ability of ARPCA peptide to
antagonize the activity of FGF2 is reflected in vivo by its capacity
to suppress the angiogenic activity exerted by the growth factor in
the chick embryo CAM assay and that exerted by FGF2-overex-
pressing tumour cells in a zebrafish embryo/tumour graft assay.
Thus, ARPCA peptide is endowed with a significant FGF2-antago-
nist activity in vitro and in vivo.
Various amino acid substitutions in the ARPCA sequence, includ-
ing the removal of the N-terminal blocking acetyl group, cause a dra-
matic decrease in the FGF2-antagonist activity of the corresponding
mutated synthetic pentapeptides (see Table 2), pointing to the rele-
vance of each amino acid residue for ARPCA/FGF2 interaction. On
the other hand, STD NMR experiments demonstrate that only the
methyl protons of Ala1, Ala5 and of the N-terminal blocking acetyl
group receive saturation transfer following FGF2 interaction, indicat-
ing that these groups are the main responsible to make a direct con-
tact with FGF2 protein. This suggests that the RPC sequence plays a
conformational role in ARPCA/FGF2 interaction and may help to ori-
ent the methyl groups of the peptide for optimal interaction with the
growth factor. This hypothesis is supported by the lack of FGF2-
antagonist activity of the partially scrambled Ac-APCRA-NH2 mutant
and of the scrambled Ac-PARAC-NH2 mutant. In addition, STD NMR
experiments show a reduced STD amplification factor for the methyl
groups of the Ac-ARPSA-NH2 mutant (data not shown), thus indicat-
ing a lower affinity of interaction that results in the lack of FGF2-
antagonist activity. Relevant to this point, it is worth noticing that
STD NMR experiments were performed under reducing conditions in
order to prevent the potential formation of disulphide bridges
between Cys4 residues of two ARPCA molecules, leading to the for-
mation of ARPCA dimers, or between Cys4 of ARPCA and free cys-
teines in the FGF2 protein. Moreover, the observation that amino acid
substitution of the cysteine residue or changing its position in the
partially scrambled peptide mutants result in a significant inhibition
of the FGF2-antagonist activity of the corresponding peptide points
to conformational role of Cys4 in ARPCA/FGF2 interaction.
The extracellular portion of FGFRs comprises three Ig-like
domains (D1, D2 and D3, with an acidic box between D1 and D2).
Their ligand binding and specificity reside in D2, D3 and D2-D3
linker region. X-ray crystallography has shown that the interac-
tions between FGF2 and D3 are of both hydrophobic and polar
character whereas the interactions with the D2-D3 linker are medi-
ated mainly via hydrogen bonds. At variance, hydrophobic interac-
tions dominate the interface between FGF2 and D2 [50]. Indeed,
hydrophobic residues from discontinuous regions in FGF2, includ-
ing Tyr-24, Phe-31, Tyr-103, Leu-140 and Met-142, form a flat sol-
vent-exposed hydrophobic surface which interacts hydrophobi-
cally with Leu-165, Ala-167, Pro-169 and Val-248 of the D2
domain in FGFR1. These residues are well conserved among the
four mammalian FGFRs, indicating that this hydrophobic interface
represents a highly conserved interaction site for FGF family mem-
bers [51]. On this basis, it seems possible to suggest that ARPCA
peptide may exert its FGF2 antagonist activity by mimicking the
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hydrophobic ligand-binding region of D2, thus establishing
hydrophobic interactions with the receptor-binding domain of FGF2
and competing with FGFRs for the binding to the growth factor.
Several observations support this hypothesis. (i ) As stated
above, STD NMR experiments have shown that only the methyl
protons of Ala1, Ala5 and of the N-terminal blocking acetyl group
receive saturation transfer following FGF2 interaction whereas no
evidence could be found for hydrophilic contacts between ARPCA
peptide and FGF2. Interestingly, hydrophobic interactions with
FGF2 have been observed also for the C-terminal fragment of
Platelet Factor-4 [52], a well-known anti-angiogenic FGF2 antago-
nist [53]. (ii) ARPCA prevents FGF2/FGFR1 interaction with no
effect on the heparin binding capacity of the growth factor.
Accordingly, FGFR- and heparin-binding regions represent distinct
domains in the FGF2 molecule [14]. (iii ) ARPCA inhibits FGF2
interactions with all four mammalian FGFRs. (iv) ARPCA also
inhibits the biological activity of FGF1 and FGF8b without exerting
any effect on the activity of different mitogens. (v) A model of the
proposed interaction was built by conformational analysis (see the
‘Computational methods’ paragraph in the ‘Methods’ section and
Fig. 5). The conformational analysis performed on ARPCA peptide
indicates that the most stable family of conformers show a type-I
-turn between Pro and Cys residues, thus supporting the confor-
mational role of the RPC sequence, and close distances between
Ala1 and Ala5 methyls (mean value 
 6.6  1.5 Å´). The superpo-
sition of the global minimum conformation of ARPCA peptide to
the -sheet region 164–170 of the hydrophobic domain D2 of
FGFR1 indicated that the peptide could interact with FGF2 by mim-
icking this highly conserved FGF2-binding region of the receptor.
Further experiments are required to confirm this hypothesis.
Interestingly, an anti-angiogenic peptide has been recently iden-
tified by screening a phage display heptapeptide library following
FGF2 biopanning [25]. At variance with ARPCA, this FGF2-binding
peptide shares significant amino acid homology, charge distribution
and hydrophobic profile with the Ig-like domain D3 of FGFR1 and
FGFR2. Thus, the complexity of FGF2/FGFR interaction is reflected
by the possibility to generate various FGF2 antagonists endowed
with the capacity to affect this interaction at different levels.
Fig. 4 STD NMR analysis of Ac-ARPCA-NH2/FGF2 interaction. (A) STD
spectra of Ac-ARPCA-NH2 peptide and its mutants acquired at 280 K on a
500 MHz Bruker spectrometer. (a) 1D NMR reference spectrum of 1.9 mM
Ac-ARPCA-NH2 peptide alone; (b)–(e) STD spectra of Ac-ARPCA-NH2 and
the three Ac-GRPCA-NH2, H-ARPCA-NH2 and Ac-ARPCG-NH2 peptides
recorded in the presence of 50 M FGF2 in 30 mM buffer phosphate
(95% D2O, 5% H2O), 8 mM DTT, 40 mM NaCl, pH 6.8. A saturation time
of 3 sec. was used. The assignment of the STD signals is reported. (B)
Plot of STD factors (ASDT) of the Ac-ARPCA-NH2/FGF2 system versus sat-
uration time. A 1:40 FGF2:peptide ratio was used. T1 relaxation time (sec)
of each signal is shown on the right side of the curves. (C) ASTD  (lig-
and excess) versus different concentrations of Ac-ARPCA-NH2 peptide.
Table 4 STD NMR analysis of FGF2 interaction with Ac-ARPCA-NH2
peptide and its mutants: STD amplification factors
The effect of the mutation of single methyl groups on the interaction with
FGF2 has been characterized by STD experiments. The reported STD
amplification factors were calculated as ASTD  (ligand excess). An
asterisk indicates signals which were not detectable in the STD spectra.
N-terminus Ac Ala1 Ala5
Ac-ARPCA-NH2 0.076 0.057 0.077
Ac-GRPCA-NH2 0.032 - 0.066
Ac-ARPCG-NH2 * * -
H-ARPCA-NH2 - * *
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